UK starts real-time review of Moderna's Covid-19 vaccine candidate

Moderna said earlier this month it was going to apply for real-time reviews of its experimental Covid-19 vaccine to Europe, following rolling reviews of shots of its rivals Pfizer Inc and AstraZeneca

moderna
Canada's health ministry is also in the process of reviewing Moderna's Covid-19 vaccine candidate in real time, the company said earlier this month.
Reuters
1 min read Last Updated : Oct 27 2020 | 10:25 PM IST
Moderna Inc said on Tuesday United Kingdom’s health regulator has started a real-time review of its experimental Covid-19 vaccine candidate.

The company has begun a rolling data submission from its vaccine candidate to UK’s Medicines and Healthcare products Regulatory Agency (MHRD) for it to start its independent assessment of evidence as and when it becomes available.

Such a process allows for a reduced time to approve a treatment, while maintaining the same standards of safety and effectiveness.

Moderna said earlier this month it was going to apply for real-time reviews of its experimental Covid-19 vaccine to Europe, following rolling reviews of shots of its rivals Pfizer Inc and AstraZeneca.

Canada's health ministry is also in the process of reviewing Moderna's Covid-19 vaccine candidate in real time, the company said earlier this month.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :UKCoronavirus VaccineAstraZenecaPfizerEurope

Next Story